Premier Biomedical CEO in Radio Interview Discusses Core Technology, Immunotherapy, Neuropathy Medication and Planned Series of Joint Ventures in Brazil, Asia and Europe for 2016
EL PASO, TX – (UPTICK Newswire – January 19, 2016) – Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced that their President and CEO, William A. Hartman, was interviewed by Uptick Newswire’s Everett Jolly, on his radio segment, “Stock Day,” which focuses on OTC and small cap stock companies.
The interview, which took place January 13th lasted about 15 minutes and aired January 18th. You can hear the entire interview here.
William Hartman, President and CEO, discussed Premier Biomedical’s patented core technology for treating diseases and how it differs from conventional medicine. The treatment consists of treating the bodily fluids outside the body by using smart sensors to detect the level of disease antigens in the patient’s blood or cerebral-spinal fluid, injecting antibodies into an external mixing chamber to neutralize the antigens, and then removing the antigen-antibody combination from the fluid through a dialysis process before returning the fluid to the patient. Hartman also discussed some of the latest developments being made on the immunotherapy front for fighting cancer, the company’s drug for the treatment of neuropathic pain, and a series of planned joint ventures for 2016 in Brazil, Asia and Europe which will accelerate sales and expansion of their drugs and treatments into these markets.
Contact Premier via email at firstname.lastname@example.org or by phone at (PBI) MED-7033 / (724) 633-7033.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company’s common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol “OTCQB: BIEI.” http://www.premierbiomedical.com/
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.